News Releases

Date Title View
Toggle Summary Aerie Pharmaceuticals Announces Appointment of William Coppola as Intellectual Property Counsel
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 18, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the JMP Securities 2018 Life Science Conference
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 14, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the NASDAQ 38th Investor Conference
DURHAM, N.C. --(BUSINESS WIRE)--Jun. 6, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
DURHAM, N.C. --(BUSINESS WIRE)--May 31, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Lily Nguyen as Director, Project Management
DURHAM, N.C. --(BUSINESS WIRE)--May 30, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for RoclatanTM (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%
- Submitted as a 505(b)(2) with an Expected Ten-Month FDA Review - DURHAM, N.C. --(BUSINESS WIRE)--May 15, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment
View HTML
Toggle Summary Aerie Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Business Update
Conference Call and Webcast Today, May 8 th , at 5:00 p.m. ET DURHAM, N.C. --(BUSINESS WIRE)--May 8, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development, and commercialization of first-in-class therapies for the treatment of
View HTML
Toggle Summary Aerie Pharmaceuticals Announces Appointment of Concetta Perro as Commercial Counsel
DURHAM, N.C. --(BUSINESS WIRE)--May 1, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the eye,
View HTML
Toggle Summary Aerie Pharmaceuticals Announces U.S. Launch of Rhopressa® (netarsudil ophthalmic solution) 0.02%
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 30, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma and other diseases of the
View HTML
Toggle Summary Aerie Pharmaceuticals to Announce First Quarter 2018 Financial Results and Host Conference Call on Tuesday, May 8, 2018
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 26, 2018-- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) (Aerie or the Company), announced today that its first quarter 2018 financial results will be released after the market closes on Tuesday, May 8, 2018 . Following the release, the Company will host a live
View HTML